Corvus Pharmaceuticals Inc.
CRVS | NASDAQ
$12.42
-$0.14 (-1.11%)
At close: Sep 21, 2026, 4:00 PM ET
$12.42
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 105K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -105K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -42.97M | -27.55M | -23.41M | -32.57M | -38.63M | -43.76M |
Interest Income | 2.51M | 1.82M | 1.58M | 654K | n/a | 540K |
Pretax Income | -15.28M | -62.29M | -27.03M | -41.31M | -43.24M | -6M |
Net Income | -15.28M | -62.29M | -27.03M | -41.31M | -43.24M | -6M |
Selling & General & Admin | 9.25M | 8.16M | 6.88M | 8.1M | 9.52M | 11.93M |
Research & Development | 33.72M | 19.39M | 16.53M | 24.47M | 29.12M | 31.83M |
Other Expenses | -105K | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 42.87M | 27.55M | 23.41M | 32.57M | 38.63M | 43.76M |
Interest Expense | n/a | n/a | n/a | n/a | 15K | 540K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 42.97M | 27.55M | 23.41M | 32.57M | 38.63M | 43.76M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 78.96M | 60.99M | 48.03M | 46.55M | 41.85M | 29.48M |
Shares Outstanding (Diluted) | 79.74M | 60.99M | 48.03M | 46.55M | 41.85M | 29.48M |
EPS (Basic) | -0.19 | -1.02 | -0.56 | -0.89 | -1.03 | -0.20 |
EPS (Diluted) | -0.53 | -1.02 | -0.56 | -0.89 | -1.03 | -0.20 |
EBITDA | -15.18M | -62.21M | -26.88M | -40.94M | -42.77M | -5.36M |
EBIT | -15.28M | -62.29M | -27.03M | -41.31M | -43.23M | -6M |
Depreciation & Amortization | 105K | 85K | 151K | 367K | 460K | 632K |
Add to Watchlist
Select watchlists to add or remove CRVS